Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 18/20 | 0.67 |
| ▸ | SSTR4 | P31391 | 12/20 | 0.55 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.55 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.55 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17404644 | 1.00 | SSTR2 (0.67) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL21099522 | 1.00 | SSTR2 (0.66) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL22183435 | 0.95 | SSTR2 (0.61) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18359971 | 0.93 | SSTR2 (0.68) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18359859 | 0.92 | SSTR2 (0.67) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL20963118 | 0.92 | SSTR2 (0.67) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18359860 | 0.92 | SSTR2 (0.68) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18359848 | 0.92 | SSTR2 (0.68) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL17404642 | 0.92 | SSTR2 (0.69) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL18712923 | 0.92 | SSTR2 (0.69) | SSTR2SSTR4SSTR5SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9750818-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | SSTR2 4/4885SSTR4 3/4885SSTR5 1/4885 |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | SSTR2 4/4885SSTR4 3/4885SSTR5 1/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | SSTR2 4/4885SSTR4 3/4885SSTR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.